Sarcoidosis is a complex disease with heterogeneous clinical presentations that can affect
virtually any organ. Although the lung is typically the most common organ involved …

Sarcoidosis is a multisystem granulomatous disease with nonspecific clinical manifestations
that commonly affects the pulmonary system and other organs including the eyes, skin, liver …

Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …

Sarcoidosis is an idiopathic inflammatory disorder that is commonly treated with
glucocorticoids. An imprecise understanding of the immunologic changes underlying …

Sarcoidosis is a systemic disease of unknown etiology defined by the presence of
noncaseating granulomatous inflammation that can cause organ damage and diminished …

Increased levels of tumor necrosis factor (TNF) α have been linked to a number of
pulmonary inflammatory diseases including asthma, chronic obstructive pulmonary disease …

Rationale: Pulmonary sarcoidosis is classically defined by T-helper (Th) cell type 1
inflammation (eg, IFN-γ production by CD4+ effector T cells). Recently, IL-17A–secreting …

Pulmonary sarcoidosis presents substantial management challenges, with limited evidence
on effective therapies and phenotypes. In the absence of definitive evidence, expert …

Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …

Objective: To describe clinical and imaging responses in neurosarcoidosis to infliximab, a
monoclonal antibody against tumor necrosis factor–α. Methods: Investigators at 6 US …